Overview of Dr. Evering
Dr. Teresa Evering is an infectious disease specialist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and New York-Presbyterian Hospital. She received her medical degree from Weill Cornell Medicine and has been in practice 20 years. She is one of 140 doctors at New York-Presbyterian Hospital and one of 140 doctors at New York-Presbyterian Hospital who specialize in Infectious Disease. She has more than 30 publications and over 500 citings.
Office
455 1st Ave
7TH floor
New York, NY 10016- Is this information wrong?
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Infectious Disease, 2000 - 2004
Icahn School of Medicine at Mount Sinai (New York Eye and Ear Infirmary at Mount Sinai)Residency, Otolaryngology - Head and Neck Surgery, 1998 - 2002
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
Weill Cornell MedicineClass of 1997
Certifications & Licensure
NY State Medical License 2000 - 2025- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- Molecular Epidemiologic and Geo-Spatial Characterization ofCultured from Skin and Soft Tissue Infections from United States-Born and Immigrant Patients Living in New Y...Lilly Cheng Immergluck, Xiting Lin, Ruijin Geng, Mike Edelson, Fatima Ali, Chaohua Li, T J Lin, Chamanara Khalida, Nancy Piper-Jenks, Maria Pardos de la Gandara, Hermi...> ;Antibiotics. 2023 Oct 14
- Cellular rejuvenation to combat HIV-1-related neurocognitive impairment.Philipp N Ostermann, Teresa H Evering> ;Trends in Microbiology. 2024 Jan 1
- Long COVID After Bamlanivimab Treatment.Teresa H Evering, Carlee B Moser, Nikolaus Jilg, Eunice Yeh, Busola Sanusi, David A Wohl, Eric S Daar, Jonathan Z Li, Paul Klekotka, Arzhang Cyrus Javan, Joseph J Eron...> ;The Journal of Infectious Diseases. 2023 Aug 31
- Join now to see all
Press Mentions
Trial Shows Strong COVID Protection in Antibody CombinationApril 25th, 2023- Antibody Combo Provides Robust Protection Against Severe COVID-19 in Large International Trial | EditorialApril 19th, 2023
- Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021October 4th, 2021
Hospital Affiliations
New York-Presbyterian HospitalNew York, New York- New York-Presbyterian HospitalNew York, New York
